



### I. Epidemiological profile

Population	2013	%
Number of active foci	0	
Number of people living within active foci	0	0
Number of people living in malaria-free areas	222 000	100
Total	222 000	


Parasites and vectors			
Major plasmodium species: <i>P. falciparum</i> (100%), <i>P. vivax</i> (0%)			
Major anopheles species: <i>An. funestus</i> , <i>An. gambiae</i>			
Programme phase: Elimination			
Total confirmed cases, 2013:	82	Indigenous cases, 2013:	1
Total deaths, 2013:	0	Indigenous deaths, 2013:	0

### II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Year adopted
<b>ITN</b>	ITNs/LLINs distributed free of charge	Yes	2010
	ITNs/LLINs distributed to all age groups	Yes	2010
<b>IRS</b>	IRS is recommended	–	–
	DDT is authorized for IRS	No	–
<b>Larval control</b>	Use of larval control recommended	Yes	–
<b>IPT</b>	IPT used to prevent malaria during pregnancy	–	–
<b>Diagnosis</b>	Patients of all ages should receive diagnostic test	–	–
	Malaria diagnosis is free of charge in the public sector	Yes	–
<b>Treatment</b>	ACT is free for all ages in public sector	–	–
	Artemisinin-based monotherapies withdrawn	–	–
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	–
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	–
	G6PD test is a requirement before treatment with primaquine	Yes	–
	Directly observed treatment with primaquine is undertaken	Yes	–
	System for monitoring of adverse reactions to antimalarials exists	Yes	–

Intervention	Policies/strategies	Yes/No	Year adopted				
<b>Surveillance</b>	ACD for case investigation (reactive)	Yes	–				
	ACD of febrile cases at community level (pro-active)	No	–				
	Mass screening is undertaken	No	–				
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	–				
	Uncomplicated <i>P. vivax</i> cases routinely admitted	Yes	–				
	Foci and case investigation undertaken	Yes	–				
	Case reporting from private sector is mandatory	Yes	–				
Antimalaria treatment policy							
		Medicine	Year adopted				
First-line treatment of unconfirmed malaria		–	–				
First-line treatment of <i>P. falciparum</i>		AL	–				
Treatment failure of <i>P. falciparum</i>		QN	–				
Treatment of severe malaria		–	–				
Treatment of <i>P. vivax</i>		CQ+PQ	–				
Dosage of primaquine for radical treatment of <i>P. vivax</i>		–	–				
Therapeutic efficacy tests (clinical and parasitological failure, %)							
Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
–	–	–	–	–	–	–	–





### III. Financing





### Financing by intervention in 2013

No data reported for 2013

### IV. Coverage



### V. Impact



**Impact:** On track for >75% decrease in incidence 2000–2015